Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns
D. A. Rothen, P. S. Krenger, A. Nonic, I. Balke, A.-C. Vogt, X. Chang, A. Manenti, F. Vedovi, G. Resevica, S. Walton, A. Zeltins, E. Montomoli, M. Vogel, M. F. Bachmann, M. O. Mohsen
This study evaluates an intranasally administered VLP-based vaccine in a murine model, showing strong systemic and mucosal antibody responses against SARS-CoV-2 and its variants.
bioRxiv · Sep 10, 2021 · PreprintImmunology